Evidence map›Paper›PMID 37075077›Full record

ArticlePloS one2023

Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.

Clémentine Metzger, Taylor Leroy, Agathe Bochnakian, Hélène Jeulin, Anne Gegout-Petit, Karine Legrand, Evelyne Schvoerer, Francis Guillemin

Abstract readScoping Review
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Clémentine MetzgerCHRU -Nancy, INSERM, Université de Lorraine, CIC Epidémiologie clinique, F-54000, Nancy, France.ORCID 0000-0003-0712-8923
Taylor LeroyCHRU -Nancy, INSERM, Université de Lorraine, CIC Epidémiologie clinique, F-54000, Nancy, France.
Agathe BochnakianCHRU -Nancy, INSERM, Université de Lorraine, CIC Epidémiologie clinique, F-54000, Nancy, France.
Hélène JeulinUniversité de Lorraine, CNRS, LCPME, F-54000, Nancy, France.
Anne Gegout-PetitUniversité de Lorraine, CNRS, Inria, IECL, F-54000, Nancy, France.
Karine LegrandCHRU -Nancy, INSERM, Université de Lorraine, CIC Epidémiologie clinique, F-54000, Nancy, France.
Evelyne SchvoererUniversité de Lorraine, CNRS, LCPME, F-54000, Nancy, France.
Francis GuilleminCHRU -Nancy, INSERM, Université de Lorraine, CIC Epidémiologie clinique, F-54000, Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the beginning of the COVID-19 pandemic, counting infected people has underestimated asymptomatic cases. This literature scoping review assessed the seroprevalence progression in general populations worldwide over the first year of the pandemic. Seroprevalence studies were searched in PubMed, Web of Science and medRxiv databases up to early April 2021. Inclusion criteria were a general population of all ages or blood donors as a proxy. All articles were screened for the title and abstract by two readers, and data were extracted from selected articles. Discrepancies were resolved with a third reader. From 139 articles (including 6 reviews), the seroprevalence estimated in 41 countries ranged from 0 to 69%, with a heterogenous increase over time and continents, unevenly distributed among countries (differences up to 69%) and sometimes among regions within a country (up to 10%). The seroprevalence of asymptomatic cases ranged from 0% to 31.5%. Seropositivity risk factors included low income, low education, low smoking frequency, deprived area residency, high number of children, densely populated centres, and presence of a case in a household. This review of seroprevalence studies over the first year of the pandemic documented the progression of this virus across the world in time and space and the risk factors that influenced its spread.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralChildHumansPandemicsSeroepidemiologic StudiesAntibodies, Viral

Identifiers

PMID37075077
PMCPMC10118383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.